Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $325.58 million. The enterprise value is $266.82 million.
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 81.40 million shares outstanding. The number of shares has increased by 159.75% in one year.
| Current Share Class | 81.40M |
| Shares Outstanding | 81.40M |
| Shares Change (YoY) | +159.75% |
| Shares Change (QoQ) | +7.83% |
| Owned by Insiders (%) | 7.21% |
| Owned by Institutions (%) | 45.65% |
| Float | 63.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.17 |
| Forward PS | 23.02 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 22.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.13
| Current Ratio | 7.13 |
| Quick Ratio | 6.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.04 |
Financial Efficiency
Return on equity (ROE) is -7,594.60% and return on invested capital (ROIC) is -1,340.12%.
| Return on Equity (ROE) | -7,594.60% |
| Return on Assets (ROA) | -46.79% |
| Return on Invested Capital (ROIC) | -1,340.12% |
| Return on Capital Employed (ROCE) | -74.91% |
| Weighted Average Cost of Capital (WACC) | 7.59% |
| Revenue Per Employee | $427,964 |
| Profits Per Employee | -$3.82M |
| Employee Count | 28 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +312.29% in the last 52 weeks. The beta is 0.55, so Opus Genetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +312.29% |
| 50-Day Moving Average | 4.59 |
| 200-Day Moving Average | 3.23 |
| Relative Strength Index (RSI) | 45.76 |
| Average Volume (20 Days) | 1,211,254 |
Short Selling Information
The latest short interest is 5.74 million, so 7.05% of the outstanding shares have been sold short.
| Short Interest | 5.74M |
| Short Previous Month | 3.92M |
| Short % of Shares Out | 7.05% |
| Short % of Float | 9.05% |
| Short Ratio (days to cover) | 6.97 |
Income Statement
In the last 12 months, Opus Genetics had revenue of $11.98 million and -$106.93 million in losses. Loss per share was -$1.42.
| Revenue | 11.98M |
| Gross Profit | -21.45M |
| Operating Income | -43.03M |
| Pretax Income | -106.93M |
| Net Income | -106.93M |
| EBITDA | -42.98M |
| EBIT | -43.03M |
| Loss Per Share | -$1.42 |
Full Income StatementBalance Sheet
The company has $59.96 million in cash and $1.20 million in debt, giving a net cash position of $58.76 million or $0.72 per share.
| Cash & Cash Equivalents | 59.96M |
| Total Debt | 1.20M |
| Net Cash | 58.76M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | -21.10M |
| Book Value Per Share | -0.64 |
| Working Capital | 57.26M |
Full Balance SheetCash Flow
| Operating Cash Flow | -38.99M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 53,000 |
| Net Borrowing | 1.00M |
| Free Cash Flow | -38.99M |
| FCF Per Share | -$0.48 |
Full Cash Flow StatementMargins
| Gross Margin | -179.03% |
| Operating Margin | -359.13% |
| Pretax Margin | -892.36% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -159.75% |
| Shareholder Yield | -159.75% |
| Earnings Yield | -32.84% |
| FCF Yield | -11.97% |
Analyst Forecast
The average price target for Opus Genetics is $10.56, which is 164.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.56 |
| Price Target Difference | 164.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 47.02% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of -5.39 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.39 |
| Piotroski F-Score | 2 |